First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation
27.4.2026 08:00:00 CEST | Business Wire | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/
(From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers.
The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2026. The deployment expands IQM's installed base across the Asia-Pacific region, where the company already has deployed systems in South Korea and Taiwan.
TOYO will operate the quantum computer to support Japanese enterprises and researchers in developing quantum use cases, while integrating the system with high-performance computing (HPC) infrastructure and building the technical workforce Japan's quantum strategy demands.
Japan has one of the largest publicly funded national quantum programs. The country has set some of the most ambitious national quantum targets of any country — 10 million domestic users of quantum technologies and 50 trillion yen in quantum-generated production value by 2030. Meeting those targets requires more than research programs. It requires institutions that own, operate, and grow with real quantum hardware.
Commenting on the deployment, Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said: "Leading enterprises are building real quantum capabilities by owning the infrastructure, operating it, and growing with it. TOYO's commitment to this approach represents an important step in realizing Japan´s national quantum strategy based on IQM´s leading quantum computing technology."
Toshiya Kohno, Representative Director, President and CEO, TOYO Corporation, said:“Quantum technology is an essential strategic field for future economic growth, especially for the new era of Japanese manufacturing. The competition for practical implementation—such as integration with HPC, use-case development, and business talent development—has already begun, moving beyond theory and research. With the cooperation of IQM, we will promote the social implementation of quantum technologies in Japan ahead of the world.”
About IQM Quantum Computers:
IQM Quantum Computers is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM's on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018, headquartered in Finland, it has over 350 employees. IQM operates across Europe, Asia, and North America. IQM has announced its plans to become the first publicly listed European quantum company on a major U.S. stock exchange by merging with Real Asset Acquisition Corp. (Nasdaq: RAAQ); with a dual listing on the Helsinki Stock Exchange also under consideration.
About TOYO Corporation:
TOYO Corporation (Head Office: Tokyo, Japan) contributes to technological innovations as a leading provider of advanced measurement solutions. Through its variety of business segments - Sustainable Energy, Advanced Mobility, ICT (Information and Communication Technologies) and Information Security, EMC (Electromagnetic Compatibility) and Antenna Systems, Defense and Security, Ocean, Software Quality and Productivity, Life Science, and Quantum Solutions, the company is focused on providing solutions to emerging markets such as clean energy and autonomous vehicle development. TOYO also makes significant R&D investments to develop in-house technologies and products, and its growth strategies include investing in new business, conducting M&A, and developing its market presence in global markets. By making available the most advanced market-based solutions, TOYO is at the forefront of helping to shape a safe and environmentally-friendly society and develop industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260426053944/en/
Contacts
IQM Media contact:
Email: press@meetiqm.com
Mobile: +358 (0) 50 479 0845
TOYO Media contact:
Email: marketing_pr@toyo.co.jp
Mobile: +81 (0) 3-3279-0771
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom